Literature DB >> 22037726

[Late complications after chemical burns of the ocular surface. Surgical strategies for ocular surface reconstruction].

B Bachmann1, C Cursiefen.   

Abstract

Severe chemical burns of the ocular surface frequently result in long-standing and ongoing disorders of the conjunctiva and the cornea including conjunctival scarring with shortening of the fornix, cicatricial entropion, complications caused by trichiasis and scarring or chronic ulceration of the cornea. Advanced destruction of limbal stem cells leads to limbal stem cell deficiency with conjunctivalization of the cornea. Surgical therapy aims at the correction of malpositioning of the lids, the reconstruction of the conjunctiva and the fornix utilizing applicable tissue grafts and the reestablishment of a stable, avascular and transparent corneal epithelium by e.g. transplantation of epithelial stem cells. Progressive corneal ulcerations unresponsive to medical therapy can be treated by amniotic membrane transplantation, corneal transplantation or by conjunctival covering depending on the extent of damaged tissue. The surgical therapy of patients after severe chemical burns of the ocular surface is generally performed in specialized centers and occasionally requires a multidisciplinary approach.

Entities:  

Mesh:

Year:  2011        PMID: 22037726     DOI: 10.1007/s00347-010-2251-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  69 in total

Review 1.  Midterm results of cultivated autologous and allogeneic limbal epithelial transplantation in limbal stem cell deficiency.

Authors:  Mikk Pauklin; Thomas A Fuchsluger; Henrike Westekemper; Klaus-P Steuhl; Daniel Meller
Journal:  Dev Ophthalmol       Date:  2010-05-18

2.  Results of buccal mucosal grafting for patients with medically controlled ocular cicatricial pemphigoid.

Authors:  J W Shore; C S Foster; C T Westfall; P A Rubin
Journal:  Ophthalmology       Date:  1992-03       Impact factor: 12.079

3.  Amniotic membrane-covered bio-onlays for treatment of ocular surface disease.

Authors:  C Cursiefen; C Rummelt; M W Beckmann; F E Kruse
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

4.  Conjunctival transplantation.

Authors:  R A Thoft
Journal:  Arch Ophthalmol       Date:  1977-08

Review 5.  [Clinical management of severe ocular surface disease].

Authors:  J Stoiber; G Grabner
Journal:  Klin Monbl Augenheilkd       Date:  2005-07       Impact factor: 0.700

6.  Corneal reconstruction with tissue-engineered cell sheets composed of human immature dental pulp stem cells.

Authors:  José Alvaro Pereira Gomes; Bábyla Geraldes Monteiro; Gustavo Barreto Melo; Ricardo Luiz Smith; Marcelo Cavenaghi Pereira da Silva; Nelson Foresto Lizier; Alexandre Kerkis; Humberto Cerruti; Irina Kerkis
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

Review 7.  The oral mucosa graft: a systematic review.

Authors:  Michael R Markiewicz; Melissa A Lukose; Joseph E Margarone; Guido Barbagli; Kennon S Miller; Sung-Kiang Chuang
Journal:  J Urol       Date:  2007-06-11       Impact factor: 7.450

8.  Tarsal grafting for correction of cicatricial entropion.

Authors:  H I Baylis; C Hamako
Journal:  Ophthalmic Surg       Date:  1979-07

9.  [Retrospective study of severe alkali burns of the eyes].

Authors:  R Kuckelkorn; W Makropoulos; A Kottek; M Reim
Journal:  Klin Monbl Augenheilkd       Date:  1993-12       Impact factor: 0.700

10.  Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium.

Authors:  G Pellegrini; C E Traverso; A T Franzi; M Zingirian; R Cancedda; M De Luca
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

View more
  1 in total

1.  Effect of vasoactive intestinal peptide on the wound healing of alkali-burned corneas.

Authors:  Nese Tuncel; Nilgun Yildirim; Firdevs Gurer; Hikmet Basmak; Kubilay Uzuner; Varol Sahinturk; Huseyin Gursoy
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.